Founded in Quebec City in 2015, diaMentis is the first company to develop a software as medical device (SaMD) that analyses information from a simple examination of the eye (electroretinography). Mission: Develop, valorise, patent and market (directly or indirectly) a diagnostic tool for better management of patients with mental disorders in a personalised healthcare environment. diaMentis value proposition: • A non-invasive, not expensive and easy to implement test • A reliable method of analysis • Fast results via a centralized service diaMentis technology will lead to: • More accurate and faster diagnosis • Appropriate choice of treatments and psychotherapy • Better acceptance of the disease by the patient and better monitoring of treatments • Reduction in relapses • Decrease in duration and number of hospitalizations • Return to work faster (reduction of disability premiums and family pressure)